Sunday, September 25, 2022
wellness India Expo
Home Tags Trials

Tag: Trials

Pfizer initiates Phase 3 Study of mRNA-based Influenza vaccine

First Phase 3 efficacy study to be conducted using an mRNA-based influenza vaccine; study will enroll 25,000 U.S. adults 18 years and older

Bharat Biotech’s iNCOVACC, world’s first Intra Nasal vaccine, gets emergency use...

Heterologous booster dose studies were conducted for safety and immunogenicity in ~875 subjects at 9 trial sites across India

“India continues to remain a key destination for clinical trials”

Jinu Jose, Vice President, Head – Sales and Clinical Operations, R&D Solutions, IQVIA India shared his views on the company's current operations, market scenario and future outlook

TB Alliance applauds WHO’s rapid communication on key changes to treatment...

New guidelines have potential to transform the TB treatment landscape with six-month standard

COVAXIN (BBV152) booster shown to neutralize both Omicron & Delta variants...

100% of test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant

COVAXIN booster dose study shows promising results

The phase 2, double-blind, randomised controlled COVAXIN trial demonstrated long-term safety with no serious adverse events

Pandemic offers opportunities to scale up interventions for the mental health...

It is time to prioritize the mental and physical wellbeing of those who every day are facing the worst of the pandemic on the frontlines

Eminent scientists & agriculturists calls on govt to allow BRL1 field...

Considering the time and investment that go into developing a product or technology and for conducting field trials a science-based neutral approach is required...................

Phase-3 trial results show COVAXIN is 77.8% effective against symptomatic COVID-19

Efficacy analysis demonstrates COVAXIN to be 93.4% effective against severe symptomatic COVID-19. Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant..................................

COVAXIN demonstrates interim clinical efficacy of 78% in phase 3 trials

The second interim results showed India’s First COVID-19 Vaccine had demonstrated strong primary efficacy against severe COVID-19 disease.......................